Tailored study design & rapid initiation
Advance preclinical obesity candidates with speed and certainty
Gubra has extensive experience with diet-induced obese (DIO) animals and has successfully profiled numerous anti-obesity drug candidates in these translational models. Our preclinical CRO services include efficacy and mode-of-action studies on weight loss drugs, utilizing state-of-the-art in vivo, biochemical, histological and NGS technologies.
Explore our 2026 American Diabetes Association (ADA) Scientific Sessions data
Download Gubra’s ADA 2026 Posters
Download the latest research and explore how we can help accelerate the development of your preclinical drug candidate with conclusive data on weight loss efficacy and mode-of-action.
Discover more from our anti-obesity research
Related Publications
Use whole brain c-Fos imaging to understand your obesity compound’s effects in the CNS
PROGRESS YOUR STUDY WITH GREATER CERTAINTY
High-resolution 3D whole-hindlimb imaging for quantitative muscle endpoints
Drug development for sarcopenic obesity requires multidimensional assessment of muscle structure, mass, and function. Gubra’s 3D imaging platform enables automated quantification of multiple histological endpoints in intact rodent hind limbs, integrated with in vivo metabolic and functional data to deliver robust, data-driven insights for your drug candidate.
“
We are experts in bridging preclinical and clinical drug development.
MARCO TOZZI Principal Scientist
Marco has a strong background within preclinical obesity and diabetes research. Reach out to Marco to get valuable scientific guidance in the design and execution of preclinical obesity/diabetes studies and how to optimally profile anti-obesity/diabetes drugs.
Are you interested to hear more?
Contact us
Gubra
Hørsholm Kongevej 11B
2970 Hørsholm
Denmark
+45 3152 2650